Ziga Ude
Ziga Ude has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Celine J. Marmion
Royal College of Surgeons in Ireland
4 shared publications Brendan Twamley
School of Chemistry, Trinity College Dublin, University of Dublin College Green, Dublin 2, Ireland
2 shared publications- Andrew Kellett
Research Ireland Centre for Pharmaceuticals School of Chemical Sciences Dublin City University Dublin Ireland
1 shared publication - Deirdre Fitzgerald-Hughes
Clinical Microbiology, Royal College of Surgeons in Ireland, RCSI Education and Research, Beaumont Hospital, Beaumont, Dublin, D09YD60, Ireland
1 shared publication Elisa Esteve Codina
Department of Chemistry and Biochemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, SI-1000 Ljubljana, Slovenia
1 shared publicationGerard Sheehan
SSPC Pharma Research Centre, Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland
1 shared publication
Latest Publications
- 1 December 2021
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 58 (6) , 106449
Multi-targeted metallo-ciprofloxacin derivatives rationally designed and developed to overcome antimicrobial resistance
- 1 December 2021
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 58 (6) , 106449
Multi-targeted metallo-ciprofloxacin derivatives rationally designed and developed to overcome antimicrobial resistance
- 4 April 2019
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 48 (24) , 8578-8593
A new class of prophylactic metallo-antibiotic possessing potent anti-cancer and anti-microbial properties
Immunocompromised cancer patients are often at high risk of developing infections. Standard infection control measures are required to prevent the onset of infection but, under some circumstances, antimicrobial prophylaxis is necessary. We have developed a family of innovative metallo-antibiotics of general formula [Cu(N,N)(CipA)Cl] where N,N represents a phenanthrene ligand and CipA stands for a derivative of the clinically used fluoroquinolone antibiotic ciprofloxacin. The X-ray crystal structure of one member from this family, [Cu(phen)(CipA)Cl] (where phen is 1,10-phenanthroline), is also reported. These complexes combine into one drug entity a Cu-N,N-framework with DNA binding and DNA oxidant properties and an antibiotic derivative with known anti-proliferative and anti-microbial activities. The complexes were all found to exhibit excellent DNA recognition with binding affinity of lead agents in the order of ∼107 M(bp)−1. Biophysical studies involving calf thymus DNA indicate the complexes intercalate or semi-intercalate DNA via the minor groove. All complexes exhibited excellent nuclease activity with DNA strand scission being mediated predominantly via superoxide and hydroxyl radicals. The complexes were found to have promising anti-proliferative effects against a human breast adenocarcinoma cell line (MCF-7) and a human prostate carcinoma cell line (DU145) with low micromolar and, in some cases, nanomolar cytotoxicities observed. Selective targeting of Gram positive bacteria was also identified by this complex class with one lead compound having an order of magnitude greater potency against Methicillin-resistant S. aureus (MRSA) as compared to the CipA ligand. Importantly, from a clinical stand point, these complexes were also found to be well tolerated in an in vivo Galleria mellonella larvae model, which has both functional and structural similarities to that of the innate immune system of mammals.
- 4 April 2019
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 48 (24) , 8578-8593
A new class of prophylactic metallo-antibiotic possessing potent anti-cancer and anti-microbial properties
Immunocompromised cancer patients are often at high risk of developing infections. Standard infection control measures are required to prevent the onset of infection but, under some circumstances, antimicrobial prophylaxis is necessary. We have developed a family of innovative metallo-antibiotics of general formula [Cu(N,N)(CipA)Cl] where N,N represents a phenanthrene ligand and CipA stands for a derivative of the clinically used fluoroquinolone antibiotic ciprofloxacin. The X-ray crystal structure of one member from this family, [Cu(phen)(CipA)Cl] (where phen is 1,10-phenanthroline), is also reported. These complexes combine into one drug entity a Cu-N,N-framework with DNA binding and DNA oxidant properties and an antibiotic derivative with known anti-proliferative and anti-microbial activities. The complexes were all found to exhibit excellent DNA recognition with binding affinity of lead agents in the order of ∼107 M(bp)−1. Biophysical studies involving calf thymus DNA indicate the complexes intercalate or semi-intercalate DNA via the minor groove. All complexes exhibited excellent nuclease activity with DNA strand scission being mediated predominantly via superoxide and hydroxyl radicals. The complexes were found to have promising anti-proliferative effects against a human breast adenocarcinoma cell line (MCF-7) and a human prostate carcinoma cell line (DU145) with low micromolar and, in some cases, nanomolar cytotoxicities observed. Selective targeting of Gram positive bacteria was also identified by this complex class with one lead compound having an order of magnitude greater potency against Methicillin-resistant S. aureus (MRSA) as compared to the CipA ligand. Importantly, from a clinical stand point, these complexes were also found to be well tolerated in an in vivo Galleria mellonella larvae model, which has both functional and structural similarities to that of the innate immune system of mammals.
- Open Access
- 1 July 2016
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 160, 210-217
A novel dual-functioning ruthenium(II)–arene complex of an anti-microbial ciprofloxacin derivative — Anti-proliferative and anti-microbial activity
- 1 July 2016
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 160, 210-217
Open AccessA novel dual-functioning ruthenium(II)–arene complex of an anti-microbial ciprofloxacin derivative — Anti-proliferative and anti-microbial activity
- Open Access
- 20 June 2016
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 45 (29) , 11791-11800
Pyrithione-based ruthenium complexes as inhibitors of aldo–keto reductase 1C enzymes and anticancer agents
Four ruthenium complexes of clinically used zinc ionophore pyrithione and its oxygen analog 2-hydroxypyridine N-oxide were prepared and evaluated as inhibitors of enzymes of the aldo–keto reductase subfamily 1C (AKR1C). A kinetic study assisted with docking simulations showed a mixed type of inhibition consisting of a fast reversible and a slow irreversible step in the case of both organometallic compounds 1A and 1B. Both compounds also showed a remarkable selectivity towards AKR1C1 and AKR1C3 which are targets for breast cancer drug design. The organoruthenium complex of ligand pyrithione as well as pyrithione itself also displayed toxicity on the hormone-dependent MCF-7 breast cancer cell line with EC50 values in the low micromolar range.
- 20 June 2016
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 45 (29) , 11791-11800
Open AccessPyrithione-based ruthenium complexes as inhibitors of aldo–keto reductase 1C enzymes and anticancer agents
Four ruthenium complexes of clinically used zinc ionophore pyrithione and its oxygen analog 2-hydroxypyridine N-oxide were prepared and evaluated as inhibitors of enzymes of the aldo–keto reductase subfamily 1C (AKR1C). A kinetic study assisted with docking simulations showed a mixed type of inhibition consisting of a fast reversible and a slow irreversible step in the case of both organometallic compounds 1A and 1B. Both compounds also showed a remarkable selectivity towards AKR1C1 and AKR1C3 which are targets for breast cancer drug design. The organoruthenium complex of ligand pyrithione as well as pyrithione itself also displayed toxicity on the hormone-dependent MCF-7 breast cancer cell line with EC50 values in the low micromolar range.
- Open Access
- 1 January 2016
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 8 (1) , 43-60
Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer
A comprehensive overview showcasing how liposomes, nanocapsules, polymers, dendrimers, nanoparticles and nanotubes may be employed as vehicles to selectively deliver cytotoxic platinum drug payloads to tumour cells.
- 1 January 2016
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 8 (1) , 43-60
Open AccessExploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer
A comprehensive overview showcasing how liposomes, nanocapsules, polymers, dendrimers, nanoparticles and nanotubes may be employed as vehicles to selectively deliver cytotoxic platinum drug payloads to tumour cells.